MARKET

IMMP

IMMP

Immutep
NASDAQ
2.550
-0.070
-2.67%
Opening 11:50 12/19 EST
OPEN
2.560
PREV CLOSE
2.620
HIGH
2.585
LOW
2.520
VOLUME
114.19K
TURNOVER
--
52 WEEK HIGH
3.530
52 WEEK LOW
1.320
MARKET CAP
375.80M
P/E (TTM)
-9.1958
1D
5D
1M
3M
1Y
5Y
1D
Ord Minnett Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
TipRanks · 1d ago
Immutep Highlights Progress in TACTI-004 Phase III Cancer Trial
TipRanks · 2d ago
Immutep announces progress in global TACTI-004 Phase III, enrollment continues
TipRanks · 3d ago
Immutep Reports Operational Progress In TACTI-004 Phase III Trial Evaluating Eftilagimod Alfa In Combination With MSD's Anti-PD-1 Therapy, KEYTRUDA, And Chemotherapy As First Line Therapy For Advanced/Metastatic Non-Small Cell Lung Cancer
Benzinga · 3d ago
Immutep Reports Strong Global Progress and Ongoing Enrolment in TACTI-004 Phase III Trial
Reuters · 3d ago
Weekly Report: what happened at IMMP last week (1208-1212)?
Weekly Report · 4d ago
Bell Potter Sticks to Their Buy Rating for Immutep Ltd (PRRUF)
TipRanks · 12/09 22:36
*Immutep Target Price Raised 30% to A$0.60/Share by Bell Potter>IMM.AU
Dow Jones · 12/09 21:30
More
About IMMP
Immutep Limited is an Australia-based late-stage biotechnology company. The Company is focused on developing novel immunotherapies for cancer and autoimmune disease. It is focused on advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Its lead clinical candidate is eftilagimod alfa (efti or IMP321) for the treatment of different types of cancers. Efti is the Company’s first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer. Its second in-house product candidate (IMP761) which is in clinical development for the treatment of autoimmune disease, a third product candidate, IMP731, a depleting antibody that could remove T cells involved in autoimmunity.

Webull offers Immutep Ltd - ADR stock information, including NASDAQ: IMMP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMP stock methods without spending real money on the virtual paper trading platform.